To include your compound in the COVID-19 Resource Center, submit it here.

NICE rebuffs CML drugs

The U.K.'s NICE issued draft guidance recommending against three drugs to treat chronic myelogenous leukemia (CML) in patients

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE